These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35986085)

  • 1. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
    Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
    Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
    Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of
    Tsyganov MM; Sorokovikova SS; Lutzkaya EA; Ibragimova MK
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants.
    Lucas AL; Fu Y; Labiner AJ; Dimaio CJ; Sethi A; Kastrinos F
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2686-2688.e2. PubMed ID: 36087707
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
    Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
    Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.